J Drugs Dermatol. 2023 Oct 1;22(10):SF388641s5-SF388641s9. doi: 10.36849/JDD.8641.
Eczema (also called atopic dermatitis) is a chronic, relapsing skin disease characterized by erythema, scaling, and pruritus.
Study 1. A double-blind, uncontrolled study in patients with mild-moderate eczema, ≥2 flares in prior 2 months, and baseline Scoring Atopic Dermatitis (SCORAD) score ≤15. Participants applied Eczema Flare-Up Relief Cream (EFRC) (N=65) BID for 56 days. Efficacy was assessed by SCORAD, patient-oriented SCORAD, skin sensitivity, Dermatology Life Quality Index (DLQI), and digital photography. Standard safety assessments were performed.
STUDY 2: A 21-day open study of EFRC (N=50) to evaluate tolerability as well as its effect on eczema. Results: Study 1. EFRC significantly reduced overall SCORAD scores from baseline to day 56 (11.6 to 4.9, or a 57% reduction). The patient-oriented SCORAD was reduced from 18.6 to 6.8 from baseline to day 56. At day 56, itch and pain improved in 70.4% of children and 62% of adults. DLQI scores were decreased by 75% in adults and 61% in children by day 56. Global skin sensitivity, assessed by the Sensiscale 10-item questionnaire, was 13.1 at baseline and 3.6 at day 56, an improvement of 72%.
STUDY 2: EFRC improved eczema-prone skin after 7 and 21 days. Conclusions: Study 1 showed that EFRC had good efficacy with significant reductions in overall SCORAD scores and subscores for the extent and intensity of eczema and subjective symptoms. Skin sensitivity also improved along with quality of life. Studies 2-3 also had significantly positive results and good tolerability. J Drugs Dermatol. 2023;22:10(Suppl 2):s5-9.
湿疹（也称为特应性皮炎）是一种慢性、复发性皮肤病，其特征为红斑、鳞屑和瘙痒。
研究 1. 在患有轻度至中度湿疹的患者中进行的一项双盲、非对照研究，过去 2 个月中有 ≥2 次发作，基线 Scoring Atopic Dermatitis（SCORAD）评分 ≤15。参与者应用湿疹发作缓解霜（EFRC）（N=65）每天两次，持续 56 天。通过 SCORAD、患者导向的 SCORAD、皮肤敏感性、皮肤病生活质量指数（DLQI）和数字摄影评估疗效。进行了标准的安全性评估。
研究 2：一项为期 21 天的 EFRC 开放性研究（N=50），以评估其耐受性以及对湿疹的影响。结果：研究 1. EFRC 从基线到第 56 天显著降低了总体 SCORAD 评分（从 11.6 降至 4.9，或降低 57%）。患者导向的 SCORAD 从基线的 18.6 降至第 56 天的 6.8。在第 56 天，70.4%的儿童和 62%的成年人的瘙痒和疼痛得到改善。DLQI 评分在第 56 天分别降低了 75%和 61%。通过 Sensiscale 10 项问卷评估的整体皮肤敏感性从基线的 13.1 降至第 56 天的 3.6，改善了 72%。
研究 2：EFRC 在第 7 天和第 21 天改善了易患湿疹的皮肤。结论：研究 1 表明 EFRC 具有良好的疗效，可显著降低 SCORAD 总分以及湿疹严重程度和强度以及主观症状的亚分。皮肤敏感性也随着生活质量的改善而提高。研究 2-3 也取得了显著的积极结果和良好的耐受性。J 皮肤病药物杂志。2023；22：10（增刊 2）：s5-9。
